about
Use of licensed vaccines for active immunization of the immunocompromised hostMeasles in the United Kingdom: can we eradicate it by 2010?Measles Outbreak in Pediatric Hematology and Oncology Patients in Shanghai, 2015Viral pneumonias. Infection in the immunocompromised host.Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles.Immunization of pediatric solid organ transplant candidates and recipients.Vaccination in HIV-infected adults.Challenges in measuring measles case fatality ratios in settings without vital registration.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys.Community-acquired pneumonia in immunocompromised patients. Opportunistic infections to consider in differential diagnosis.Barriers encountered during the implementation of a policy guideline on the vaccination of health care workers during the 2013-2014 measles outbreak in the Netherlands: a qualitative study.Measles vaccination: Weighing the benefits and risks of a live viral vaccine for HIV-infected childrenIndependence of measles-specific humoral and cellular immune responses to vaccinationSevere Measles Infection: The Spectrum of Disease in 36 Critically Ill Adult PatientsRisk Factors for Measles in HIV-infected Children and Adolescents in BotswanaReimmunization after hematopoietic stem cell transplantation.Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation.Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy.Immune containment and consequences of measles virus infection in healthy and immunocompromised individuals.Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of agePediatric respiratory infections by Mycoplasma pneumoniae.Use of attenuated paramyxoviruses for cancer therapy.Viral infections in immunocompromised patients.Optimizing immunization in pediatric special risk groups.Who gets measles in Europe?Fatal measles pneumonitis during Hodgkin's lymphomaVaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part II.Evolution of T Cell Responses during Measles Virus Infection and RNA Clearance.Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.Seroprevalence of transplacentally acquired measles antibodies in HIV-exposed versus HIV-unexposed infants at six months of age.The importance of immunization in cancer prevention, treatment, and survivorship.The Reemergence of Measles.Comparison of different methods and cell lines for isolating measles virus.Polymerase chain reaction for detection of measles virus in clinical samples.Case-fatality rate during a measles outbreak in eastern Niger in 2003.Protection against vaccine preventable diseases in children treated for acute lymphoblastic leukemia.British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.Serostatus following live attenuated vaccination administered before pediatric liver transplantation.International travel patterns and travel risks for stem cell transplant recipients.
P2860
Q24533456-58FAEB06-333E-48F4-8E82-34152F38183DQ24678331-D861CDD1-6C70-440F-B787-BB9EAC2E9609Q33755600-DBCF79F4-29A5-404A-9BC8-BA37315A428AQ33846623-0711AE89-844A-4F4B-8EFF-2E8DDCC3DD74Q33920185-13327BC3-F46D-4D65-BABC-B6D26461BB78Q33942411-CC274FF5-4BA3-429F-B904-A1C47F8D06A5Q33980764-E6FACBEC-F758-486C-9800-4509261F53CEQ34053811-35EE917F-E17F-4E3F-8738-D4EC2F67D4F7Q34390072-FED7AE48-0FB3-4A71-8A81-B748EF5E2DF1Q34781957-0ADC3885-B671-4B93-B417-FE3359FFB6B2Q35052571-D253B170-7CE0-49E8-8105-9ED1BA980234Q35868813-323461D1-94CC-4159-8A35-CBEEE7971CDCQ35891475-6C0D0744-2837-485A-B691-B6EDFD061CCDQ35918575-0ED9E9BC-9F12-4C50-AAEB-83D121992F46Q36008978-AF11D056-9F97-43B0-B0C4-2B354A341165Q36062346-D46E3133-2F2D-4407-8F7A-E87C1911E1BEQ36124964-67BA6C7E-03ED-47A7-84F2-3026655BED1DQ36250895-83DE3B93-34F1-414B-996B-2D6D8A5903F1Q36379247-A37E4EF7-1FE6-4B09-94D4-9B8D12DF3056Q36444231-B4B96113-DCD9-41C1-A67D-D88518475808Q36547324-1A09FF4B-3B8A-4541-974C-BA2A03FC079FQ37228742-9F4D25F9-57E5-447D-94EC-664F047291D8Q37810599-680CF810-ACF0-4299-8268-7FD9B9799DAEQ37824989-86AEDE6F-EE6C-4B98-B449-EBCE44CB855BQ37844535-4A74A9AA-C58D-41DF-BF0C-5D2D7197344EQ37888353-DD36FE34-05F1-4E9E-B040-DE49D81858E8Q38150740-02251FC2-32A3-4091-8263-F6C413AB4F08Q38638518-02BA7D45-A641-4F93-ACA6-E1B935728828Q40042285-8F9DE4E2-D493-4245-BBEE-BA64385DC939Q40044232-C210A961-7751-45AC-B11B-9E281D71BBF2Q40070937-2E87FB6A-B311-403C-B87C-BB0072FF3E30Q40104207-D19CFCC9-264B-4032-A691-8E29CF8724D8Q40136026-C5D80654-968A-4EB8-911D-90A19E699914Q40174587-E138285B-8760-4182-A6D9-C6AAFC260F41Q40174755-AD328607-D4AA-41B4-B481-D47EC91D5206Q40489525-B5CA1AE9-1E5A-4C96-9FD1-AC8E067C5374Q40513129-D125CC06-722E-4EAB-9F79-5B0269153E65Q40560650-D28C6229-1001-4721-B551-107B4ED9E9FBQ41241577-697BA905-4010-4AE3-8374-39F44750C846Q41696144-1849A322-F1F3-4B52-9C2A-5D1ADDE16716
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Severe measles in immunocompromised patients.
@ast
Severe measles in immunocompromised patients.
@en
type
label
Severe measles in immunocompromised patients.
@ast
Severe measles in immunocompromised patients.
@en
prefLabel
Severe measles in immunocompromised patients.
@ast
Severe measles in immunocompromised patients.
@en
P2093
P1476
Severe measles in immunocompromised patients.
@en
P2093
P304
P356
10.1001/JAMA.1992.03480090085032
P407
P577
1992-03-01T00:00:00Z